Management Credibility Analysis

Unavailable
Verified Management Score Unavailable
Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed
Verified Catalysts Unavailable
No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive
Not disclosed
Headquarters
13011 MCCALLEN PASS, AUSTIN, TX
Founded
Not disclosed

📈 Company Timeline

Major business events
Positive
Negative
Neutral
14 Aug 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Natera, Inc..

8 Aug 2026

Natera, Inc. securities registration filing

Natera, Inc. filed a registration or prospectus document concerning securities.

7 Aug 2026

Natera, Inc. filed Form 10-Q

Natera, Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

7 Aug 2026

Natera, Inc. reported Operating or financial results

Natera, Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

7 Jul 2026

Natera, Inc. reported A director or senior management change or compensation event

Natera, Inc. filed an 8-K covering a director or senior management change or compensation event.

Capital Structure & Financial Position

Financial strength and liquidity analysis
Cash and equivalents (USD)$466.01M
Total assets (USD)$2.66B
Total liabilities (USD)$836.00M
Shareholders' equity (USD)$1.82B
Long-term debt (USD)$282.95M

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated

Peer Comparison - Health Care

Company Price Market Cap
LLY - Eli Lilly and Company $1,276.13
Yahoo Finance 		$1.20T
JNJ - Johnson & Johnson $256.74
Yahoo Finance 		$618.71B
ABBV - AbbVie Inc. $284.80
Yahoo Finance 		$503.28B
UNH - UnitedHealth Group Incorporated $418.43
Yahoo Finance 		$375.58B
MRK - Merck & Co., Inc. $148.55
Yahoo Finance 		$366.50B

📋 Corporate Actions

Recent and upcoming corporate events
Verified Corporate Actions Unavailable
Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis
QuarterRevenue (USD)Operating incomeNet incomeDiluted EPS (USD)Filed
Q2 2026$752.75M−$75.79M−$66.97M−$0.4710-Q · 7 Aug 2026
Q1 2026$696.64M−$93.52M−$85.09M−$0.6010-Q · 8 May 2026
Q4 2025$665.50M−$22.79M$47.26MUnavailable10-K · 27 Feb 2026
Q3 2025$592.18M−$97.58M−$87.54M−$0.6410-Q · 7 Nov 2025
Q2 2025$546.60M−$110.37M−$100.94M−$0.7410-Q · 8 Aug 2025
Q1 2025$501.83M−$79.18M−$66.94M−$0.5010-Q · 9 May 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy
Target: $406.66
-1.6% upside potential
📈
Strong Buy
Unavailable
👍
Buy
18
⏸️
Hold
1
📉
Sell
0
19 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved Targets range 320.00–500.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments
Verified Dividend Data Unavailable
Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable
Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity
16
Oct 2026
Sheena Jonathan
Director
Open-market sale
$402.47 per share
1,500 shares
SEC Form 4
15
Oct 2026
Rabinowitz Matthew
Director, EXECUTIVE CHAIRMAN
Option exercise
$10.41 per share
50,000 shares
SEC Form 4
15
Oct 2026
Rabinowitz Matthew
Director, EXECUTIVE CHAIRMAN
Open-market sale
$402.64 per share
50,000 shares
SEC Form 4
7
Oct 2026
Rabinowitz Matthew
Director, EXECUTIVE CHAIRMAN
Gift
Unavailable per share
6,000 shares
SEC Form 4
1
Oct 2026
Chapman Steven Leonard
Director, CEO AND PRESIDENT
Open-market sale
$413.31 per share
1,273 shares
SEC Form 4
1
Oct 2026
Moshkevich Solomon
PRESIDENT, CLINICALDIAGNOSTICS
Open-market sale
$414.22 per share
3,000 shares
SEC Form 4
23
Sep 2026
Sheena Jonathan
Director
Open-market sale
$388.01 per share
18,064 shares
SEC Form 4
16
Sep 2026
Moshkevich Solomon
PRESIDENT, CLINICALDIAGNOSTICS
Gift
Unavailable per share
945 shares
SEC Form 4
16
Sep 2026
Sheena Jonathan
Director
Open-market sale
$354.19 per share
3,150 shares
SEC Form 4
15
Sep 2026
Sheena Jonathan
Director
Open-market sale
$350.07 per share
6,000 shares
SEC Form 4

Top Shareholders

Jpmorgan Chase & Co
12,865,346 shares
-3.894% change
6/30/2026
Vanguard Group Inc
12,306,424 shares
-0.667% change
12/31/2025
Blackrock, Inc.
10,914,608 shares
2.222% change
6/30/2026
Price T Rowe Associates Inc /Md/
9,021,895 shares
-25.958% change
6/30/2026
Vanguard Capital Management Llc
6,228,216 shares
3.657% change
6/30/2026
Vanguard Portfolio Management Llc
5,782,640 shares
2.444% change
6/30/2026
Fmr Llc
5,451,396 shares
113.424% change
6/30/2026
Wellington Management Group Llp
4,040,738 shares
-15.264% change
6/30/2026
State Street Corp
3,655,618 shares
6.968% change
6/30/2026
Duquesne Family Office Llc
3,186,306 shares
4.005% change
6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed · 4 hours ago